Mehmet Oz, M.D., says he will divest from insurance, provider and drugmakers if he earns confirmation from the Senate to run ...
Dr. Mehmet Oz has pledged to eliminate his conflicts of interest before he would helm the Centers for Medicare and Medicaid ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...
AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit ...
AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...
Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results